1. Pink Sheet
  2. >>Agency Leadership

Map To FDA RiskMAPs

 
• By Cole Werble

Increased public scrutiny of drug safety is making risk management plans de rigeur for many new chemical entities and marketed products with definable adverse effects. FDA is using a system of special review teams to determine which plans pass muster.

It’s not new for FDA approval decisions to hinge on risk management commitments by product sponsors, but the importance of these programs is clearly increasing (See "Building a Business in Drug Safety," The RPM Report, January 2006 Also see "Building a Business in Drug Safety" - Pink Sheet, 1 January, 2006..) In the past three years, the agency has reviewed 91 risk management plans; 18 of the reviews affected new molecular entities.

Risk management strategies to educate patients and medical professionals and to assure continued monitoring in the post-approval setting are becoming...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Agency Leadership

Double Duty At US FDA: Tidmarsh Will Temporarily Lead Both CDER And CBER

 
• By Sarah Karlin-Smith

Just a week and a half into his tenure at the agency, the new CDER Director George Tidmarsh was also tapped to serve as acting head of CBER. Prasad’s swift ouster at CBER may point to a softening in cell and gene therapy regulation but could also portend even more scrutiny on vaccines.

New CTIS Feature To Bridge ‘Communication Gap’ Between Trial Sponsors & EU Assessors

 
• By Vibha Sharma

A task force set up by the EMA to identify and prioritize improvements to the Clinical Trials Information System has recommended several measures to enhance CTIS’ usability and efficiency, including the potential introduction of a communication tool for direct sponsor-assessor interaction.

England’s NICE Hunts For New Chief As Sam Roberts Prepares To Step Down

 
• By Eliza Slawther

Sam Roberts, chief executive of the health technology assessment institute, NICE, will step down from her role at the end of the year. The agency is now on the lookout for a new leader, who will be the fourth in its history.

NDA User Fees Will Grow 8.6% Next Year As FDA Projects More Applications But Fewer Sponsor Meetings

 
• By Nielsen Hobbs and Derrick Gingery

The ups – and some downs – of the US FDA’s prescription, biosimilar, and generic user fees for FY 2026 are tabulated by the Pink Sheet.

More from Pink Sheet